Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-018-2223-z
Abstract: Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m2/day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking… read more here.
Keywords: melanoma; patients completely; group; hu14 il2 ... See more keywords
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
Sign Up to like & getrecommendations! Published in 2019 at "Cancers"
DOI: 10.3390/cancers11091232
Abstract: Epithelial ovarian cancer (EOC) is the fifth most common cancer affecting the female population. At present, different targeted treatment approaches may improve currently employed therapies leading either to the delay of tumor recurrence or to… read more here.
Keywords: treatment; antibody; targeted treatment; il2 immunocytokine ... See more keywords